<DOC>
	<DOCNO>NCT01527994</DOCNO>
	<brief_summary>Current treatment opioid addiction would benefit addition non-opioid base treatment medication . Recent behavioral study show neurokinin-1 ( NK1 ) receptor involve opioid reward withdrawal . This study propose study potential non-opioid treatment , clinically available , FDA approve , NK1 antagonist aprepitant , opioid addict patient . Based unique behavioral pharmacological characteristic opioid addiction , know currently employ treatment , investigator propose therapeutic mechanism potential opioid addiction treatment medication must include ability reduce opioid withdrawal . This particular importance treatment initiation ( eg . detoxification ) . In addition , long-term treatment relapse prevention , important manage drug crave inhibit reward effect opioids patient experience slip . Therefore , investigator propose study aprepitant use human model opioid withdrawal , crave acute opioid reward reinforcement . The investigator also include neuro-economics choice procedure paradigm .</brief_summary>
	<brief_title>Aprepitant Effects Intravenous Heroin Dependence</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>1 . Male female subject range age 1855 year currently opioid dependent base meeting DSMIV criterion dependence heroin either treatment nontreatment seek individual . 2 . Use intravenous heroin daily minimum 45 day prior study entry . 3 . Urine sample ( + ) opioids prior experience i.v . drug injection . 4 . Female subject childbearing potential , ( i.e . posthysterectomy , two year postmenopausal ) childbearing potential either abstain heterosexual intercourse and/or practice medically accept form contraception study duration . 5 . Subjects experience significant opioid withdrawal familiar effect . 6 . Subjects willing follow protocol requirement , include methadone study medication schedule , evidence write informed consent ability read , understand , complete study questionnaire . 1 . Subjects significant current axis1 psychiatric problem , relate drug abuse opioid dependence , base structure psychiatric interview , SCID MINI , screen process . 2 . Subjects undergo active treatment illness chronic stable medical condition ( Patients HIV and/or take antiviral HIV medication without manifestation AIDS symptom allow ) . 3 . Subjects clinically significant abnormal finding determine medical history , physical examination , vital sign ( blood pressure , heart rate , respiration rate ) , 02 saturation measure,12lead ECG , clinical laboratory test ( CBC , chemistry panel ) , urine drug screen , alcohol breath test , urine pregnancy test ( female childbearing potential ) . 4 . Subjects acute organ dysfunction serious unstable disease state include symptomatic heart , renal liver disease , COPD , sleep apnea , encephalitis . 5 . Subjects 02 saturation 90 % screening . 6 . Subjects take concomitant medication ( prescription overthecounter therapy ) include psychotropic medication treatment current major depression , schizophrenia , mood disorder , well medication contraindicate use morphine , naltrexone , aprepitant , methadone . 7 . Subjects receive investigational drug treatment within thirty ( 30 ) day precede administration study medication . 8 . Females nurse , pregnant ( confirm positive urine pregnancy test ) , risk become pregnant . 9 . Subjects allergic intolerant morphine , methadone , naloxone , aprepitant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Aprepitant</keyword>
	<keyword>Intravenous heroin dependence</keyword>
</DOC>